CONNECT WITH US
HealthTech

HealthTech

Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more

Endpoints News logo

Published on

Add as a preferred source on Google
Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more

Hel­lo and wel­come back to a spooky Hal­loween edi­tion of End­points Week­ly! Sor­ry to all the can­dy corn lovers out there, but just not­ing that …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Can­cer vac­cine da­ta from #ES­MO26; Trea­sury pro­pos­al could curb Chi­na in­vest­ment; and more October 24, 2026

A search for ‘the statin of Alzheimer’s’; Ar­row­head in­jectable low­ers tau; and more October 17, 2026

Women in Bio­phar­ma 2026; A se­cre­tive new thorn in phar­ma’s side; and more October 10, 2026

Backed by Amish and Men­non­ites, a new kind of gene ther­a­py com­pa­ny takes shape

Q&A: An­throp­ic's drug R&D chief talks catch­ing Prof. Oak, the lim­its of Claude's taste and cures vs. QALYs

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.